Yakult Honsha signed a licensing pact that allows it to market Celsion's ThermoDox, an experimental cancer treatment, in Japan. Celsion, a biotech firm in Columbia, Md., will receive $2.5 million upfront and is entitled to $18 million more once the drug gets clearance from Japanese regulators. Yakult will conduct clinical studies of ThermoDox in Japan.

Related Summaries